A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

• Status: Terminated
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and tolerability of multiple escalating doses of BMS-663513 when given in combination with paclitaxel and carboplatin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Good activity level

• Life expectancy of ≥ 6 months

• Solid tumor malignancy for which paclitaxel and carboplatin are appropriate

Exclusion Criteria:

• Major surgery within 4 weeks

• Any concurrent cancer

• History of autoimmune diseases

• Symptomatic bowel obstruction

• Continued use of steroids

• Symptomatic brain metastases

• Current nerve damage in fingers/toes

• Positive for HIV, hepatitis B/C

• White blood cells < 3,000

• Hemoglobin < 9

• Platelets < 100,000

• ALT/AST and/or alkaline phosphatase >= 2.5 x ULN

• Creatine > 1.5

• Prior BMS-663513